| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | Chief Commercial Officer | Stock Options (Right to buy) | 220,000 | $4,257,000 | $19.35 | 05 Dec 2022 | Direct |
| Turning Point Therapeutics, Inc. | SVP & Chief Commercial Officer | Common Stock | 0 | $76.00 | 17 Aug 2022 | Direct | |
| Turning Point Therapeutics, Inc. | SVP & Chief Commercial Officer | Stock Option (right to buy) | 0 | 17 Aug 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| SNDX | Syndax Pharmaceuticals Inc | 05 Dec 2022 | 1 | +$5,596,800 | 4 | Chief Commercial Officer | 05 Dec 2022, 15:41 |
| SNDX | Syndax Pharmaceuticals Inc | 05 Dec 2022 | 0 | $0 | 3 | Chief Commercial Officer | 05 Dec 2022, 15:37 |
| TPTX | Turning Point Therapeutics, Inc. | 17 Aug 2022 | 2 | -$2,786,692 | 4 | SVP & Chief Commercial Officer | 17 Aug 2022, 16:27 |
| TPTX | Turning Point Therapeutics, Inc. | 31 May 2022 | 2 | $0 | 4 | SVP & Chief Commercial Officer | 01 Jun 2022, 17:02 |
| TPTX | Turning Point Therapeutics, Inc. | 31 May 2022 | 0 | $0 | 3 | SVP & Chief Commercial Officer | 01 Jun 2022, 16:59 |